Systematic Financial Management LP Grows Stock Holdings in Integra LifeSciences Holdings Corporation $IART

Systematic Financial Management LP increased its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 4.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,108,599 shares of the life sciences company’s stock after acquiring an additional 48,094 shares during the period. Systematic Financial Management LP’s holdings in Integra LifeSciences were worth $13,769,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Amalgamated Bank boosted its holdings in Integra LifeSciences by 3.8% during the third quarter. Amalgamated Bank now owns 19,809 shares of the life sciences company’s stock worth $284,000 after buying an additional 728 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Integra LifeSciences by 6.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 14,200 shares of the life sciences company’s stock worth $205,000 after buying an additional 848 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Integra LifeSciences by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares in the last quarter. Finally, Capital Fund Management S.A. boosted its holdings in Integra LifeSciences by 5.7% during the third quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after buying an additional 1,997 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

IART has been the topic of several recent research reports. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Citigroup upped their price objective on shares of Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a research note on Wednesday, May 6th. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Wells Fargo & Company upped their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Truist Financial reduced their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Three research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Integra LifeSciences has an average rating of “Reduce” and an average price target of $12.75.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $15.10 on Monday. Integra LifeSciences Holdings Corporation has a 52-week low of $8.70 and a 52-week high of $16.49. The firm has a fifty day moving average of $11.10 and a 200-day moving average of $11.70. The firm has a market capitalization of $1.17 billion, a P/E ratio of -2.34, a PEG ratio of 1.05 and a beta of 1.08. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. During the same quarter in the prior year, the business earned $0.41 earnings per share. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, analysts predict that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.